OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children.

ABSTRACT:

Aims

This study evaluated whether one (or more) of three doses of onabotulinumtoxinA were safe and effective to treat neurogenic detrusor overactivity (NDO) in children.

Methods

This was a 48-week prospective, multicenter, randomized, double-blind study in children (aged 5-17 years) with NDO and urinary incontinence (UI) receiving one onabotulinumtoxinA treatment (50, 100, or 200 U; not to exceed 6 U/kg). Primary endpoint: change from baseline in daytime UI episodes. Secondary endpoints: change from baseline in urine volume at first morning catheterization, urodynamic measures, and positive response on the treatment benefit scale. Safety was also assessed.

Results

There was a similar reduction in urinary incontinence from baseline to Week 6 for all doses (-1.3 episode

SUBMITTER: Austin PF 

PROVIDER: S-EPMC7839517 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature